NCT06222697View on ClinicalTrials.gov

A Study to Learn More About the Safety of Damoctocog-alfa-pegol When Used in Routine Medical Care in Korean Participants With Hemophilia A

RecruitingOBSERVATIONAL
Enrollment

600

Participants

Timeline

Start Date

January 24, 2024

Primary Completion Date

March 31, 2028

Study Completion Date

May 31, 2028

Conditions
Hemophilia AProphylaxis of BleedingTreatment of Bleeding
Interventions
DRUG

Damoctocog-alfa-pegol (Jivi, BAY94-9027)

Follow clinical practice/administration. No drug is provided to participants due to the observational nature of the study.

Trial Locations (1)

Unknown

RECRUITING

Many Locations, Multiple Locations

Sponsors

Lead Sponsor

Bayer
All Listed Sponsors
lead

Bayer

INDUSTRY

NCT06222697 - A Study to Learn More About the Safety of Damoctocog-alfa-pegol When Used in Routine Medical Care in Korean Participants With Hemophilia A | Biotech Hunter | Biotech Hunter